Abiomed Announces Second Quarter Fiscal 2015 Revenue of $51.9 Million, Up 17% Over Prior Year

Abiomed on Track for Impella 2.5 and Impella RP FDA Approvals by February/March 2015

DANVERS, Mass., Oct. 30, 2014 -- Abiomed, Inc. (ABMD), a leading provider of breakthrough heart support technologies, today reports second quarter fiscal 2015 revenue of $51.9 million, an increase of 17% compared to revenue of $44.3 million for the same period of fiscal 2014. Second quarter fiscal 2015 GAAP net income was $3.8 million or $0.09 per diluted share, compared to GAAP net income of $1.1 million or $0.03 per diluted share for the prior year period.

Wright Medical Group, Inc. and Tornier N.V. Agree to Merge Creating Premier High-Growth Extremities-Biologics Company

Combination Will Offer Comprehensive Upper and Lower Extremity Product Portfolio and Broad Global Reach
Further Accelerates Growth Opportunities in Three of the Fastest Growing Areas in Orthopaedics
Adds Significant Scale and Scope to Provide Accelerated Path to Profitability and Stronger Financial Profile
Wright Receives Approvable Letter from FDA for Augment
® Bone Graft
Wright and Tornier Management to Host Joint Conference Call Today at 4:30 p.m. Central Time

MEMPHIS, Tenn. & AMSTERDAM--- Wright Medical Group, Inc. (WMGI) and Tornier N.V. (TRNX) announced today that they have entered into a definitive merger agreement under which Wright and Tornier will combine in an all stock transaction with a combined equity value of approximately $3.3 billion.

TSO3 in Label Review for its STERIZONE® Sterilization System - Company to submit Final Labeling to US Regulatory Authorities for Sterilizer accessories

QUÉBEC CITY, Oct. 22, 2014 - TSO3 Inc. (TOS.TO) ("TSO3" or the "Corporation") an innovator in sterilization technology for medical devices in healthcare settings, today announced that after a series of communications with US Regulatory Authorities, the Company has submitted revised labeling for the sterilizer, and is now finalizing labeling for accessory devices such as the Biological and Chemical Indicators used as part of the sterilization system.  Such revisions are required so that all components of the entire system (sterilizer and accessories) can be in final review simultaneously.

Alpha Pro Tech, LTD. Announces Financial Results for the Third Quarter Ended September 30, 2014

Record Quarterly Building Supply Segment Sales of $8.5 Million
Income from Operations Increased 15.6% for the Third Quarter and Increased 32.2% Year to Date

  • Net sales increased 4.1% to $13.2 million for the quarter ended September 30, 2014, compared to $12.7 million for the quarter ended September 30, 2013, and increased 6.4% to $35.4 million for the nine-month period ended September 30, 2014 from $33.3 million for the comparable nine-month period of 2013.

Theralase Presents Latest Research on Destruction of Cancer and Bacteria at International Conference

Toronto, Ontario -- October 16, 2014 / Theralase Technologies Inc. ("Theralase(R)") (TSXV: TLT) (TLTFF: OTC Link(R)) announced today that it has presented its latest research on the success of its Photo Dynamic Compounds ("PDCs") in the destruction of cancer and bacteria. This research was presented at the 10th International Symposium on Photodynamic Therapy and Photodiagnosis in Clinical Practice, taking place in Brixen, Italy from October 14 to 18, 2014.

http://theralase.com/wp-content/uploads/2014/10/Biophysical-in-vitro-ex-vivo.pdf

Cancer remains one of the top human conditions and effective minimal or non-invasive treatments with low side effects and high success rates are urgently needed. Photo Dynamic Therapy ("PDT"), the combination of a Photo Dynamic Compound ("PDC") and a specific wavelength of light to produce cytotoxic (cell death) oxygen species, has been shown to be a promising avenue for cancer treatment.